Diabetic Retinopathy Eye Diseases Retinal disorders in diseases classified elsewhere
Conditions
Interventions
1. The sulindac group: patients took 100 mg of sulindac twice a day
2. The epalrestat group: patients took 50 mg of epalrestat three times a day
3. The control group: patients took no additional med
Sponsors
Asama General Hospital (Japan)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Clinical diagnosis of type two diabetes 2. Age 20 years or older 3. Patient consent
Exclusion criteria
Exclusion criteria: 1. Having diabetes for less than five years 2. HbA1c less than 8.0% 3. Taking other medications except for oral hypoglycemic agents or insulin injections 4. Hypertension 5. Inability to understands the implications of the the protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Seven-field stereoscopic retinal photography at baseline, and yearly intervals 2. Endpoint if they were diagnosed with proliferative diabetic retinopathy | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Glycosylated Hemoglobin (GHb) values determine at monthly intervals 2. Remain on their medications for three years 3. Endpoint if exhibited a dipstick proteinuria of more than or equal to 1+ | — |
Countries
Japan
Outcome results
None listed